Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

2004579 citationsJournal Article

Authors

These data suggest that bortezomib was well tolerated and has significant single-agent activity in patients with certain subtypes of NHL.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 23, Issue 4, pp. 676-684

Field-Weighted Citation Impact: 18.24